Philips tells Lumify ultrasound users to keep backup scanners after four reported deaths
Philips told all Lumify handheld ultrasound customers to keep backup scanners on hand after a device issue linked to four deaths and eight serious injuries. The FDA says ambulance and field crews face the greatest risk, because clearing the fault takes a Wi-Fi or cellular signal that is harder to find outside the hospital.
Publishers:fda.gov
Reality
- Evidence58
- Adoption
- Not scored
- Hype gap0
- Incentives
- Not scored
- Confidence62
HLB's fourth rivoceranib filing hinges on two factories' FDA inspection ratings
HLB is preparing a fourth FDA filing for its liver cancer drug rivoceranib after both manufacturing sites tied to it received VAI inspection ratings. Manufacturing problems ran through all three rejections, so those ratings say more about rivoceranib's odds than HLB's first FDA approval does.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+25
- Incentives70
- Confidence50
FDA moves to extend its packaging-chemical exemption to ingredients added to food
FDA's proposed GRAS rule would let some chemicals below 0.5 parts per billion go directly into food without a safety review, the Guardian reported. Advocates say substances that harm at far lower doses could in theory qualify.
Reality
- Evidence45
- Adoption
- Not scored
- Hype gap+30
- Incentives50
- Confidence40
Epilepsy drug lacosamide pushes damaged cartilage toward repair in Yale's preclinical osteoarthritis work
Yale researchers report that lacosamide, an FDA-approved epilepsy drug, eased joint pain and reversed cartilage damage in preclinical osteoarthritis studies. No FDA-approved medicine yet does both for osteoarthritis, so the open question is whether the effect holds in people.
Reality
- Evidence30
- Adoption
- Not scored
- Hype gap+40
- Incentives65
- Confidence35
Lotte Biologics will make drug substance for several Alvotech antibody biosimilars at its 40,000-liter plant in Syracuse, New York. Alvotech's CEO said its network now covers a decade of pipeline demand, so more work for Lotte depends on how many Alvotech products launch.
Reality
- Evidence45
- Adoption25
- Hype gap+20
- Incentives70
- Confidence60
HLB's Lypictu enters EU review chasing an FGFR2 market about 40% smaller than America's
HLB's lirafugratinib entered full EMA review on Oct. 1, eight days after the FDA approved the bile duct cancer drug as Lypictu. Industry sources put Europe's FGFR2 segment at $65 million against $110 million in the US, so most of the commercial case rests on American prescriptions.
Reality
- Evidence55
- Adoption10
- Hype gap+10
- Incentives60
- Confidence50
Pulse oximeter error at Johns Hopkins reversed direction over five years of ICU data
Johns Hopkins researchers found pulse oximeters in their ICUs shifted from overestimating to underestimating blood oxygen across five years of records. Because the error changed direction at higher oxygen levels, a skin-tone correction set once would have been wrong before the period ended.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+5
- Incentives50
- Confidence50
PepsiCo has recalled about 122,000 Gatorade cases in 37 states because the bottles contain Yellow No. 5 and/or No. 6 dyes their labels omit. The FDA rated it class II, a category for temporary or reversible harm, so a labelling error on its own produced a recall of this size.
Reality
- Evidence72
- Adoption
- Not scored
- Hype gap0
- Incentives
- Not scored
- Confidence70
Stem cell industry bets the FDA's peptide opening will let it in next
Stem cell entrepreneur Chuck Meeker predicts a series of FDA roundtables on his industry's therapies before the end of the year. The agency declined to say whether any are planned, so for now the forecast tells us more about what the industry hopes than about what the FDA intends.
Reality
- Evidence30
- Adoption
- Not scored
- Hype gap+45
- Incentives80
- Confidence35
The panel was unanimous that Grail's Galleri is safe and divided six to four on whether it is effective, on evidence in which 287 of more than 35,000 people screened got a cancer signal and about 60 percent of those were diagnosed.
Perspective Coverage
3 publishers
- Builder
- Builder 22%
- Operator
- Operator 43%
- Investor
- Investor 35%
Reality
- Evidence62
- Adoption
- Not scored
- Hype gap+35
- Incentives55
- Confidence58
FDA's chief scientist plans to list aging among the agency's fiscal 2027 regulatory science priorities
FDA Chief Scientist Steven Kozlowski says aging and longevity will be focus areas in the regulatory science report the agency issues in fiscal 2027. His larger aim is a shared, qualified endpoint for aging that any developer could use to run a trial and seek approval.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+10
- Incentives35
- Confidence50
Eli Lilly's 367-person trial found the top dose of tirzepatide plus eloralintide cut body weight 23.3%, against 14.8% on tirzepatide alone. Dropout ran far higher on the combination, so nobody has yet measured how much of that gain holds across everyone prescribed the pair.
Reality
- Evidence60
- Adoption
- Not scored
- Hype gap+30
- Incentives65
- Confidence55
Severe cases account for 94% of GLP-1 prescriptions to obese children aged 8 to 11
GLP-1 prescriptions for obese children aged 8 to 11 have risen 310-fold since 2019, a transplant surgeon's study found. The surgeon wants severe cases treated early but concedes that long-term data on growth and puberty are still missing.
Reality
- Evidence45
- Adoption8
- Hype gap+15
- Incentives40
- Confidence40
AriBio's Phase 3 readout decides whether Fosun pays another $80 million for AR1001
AriBio's October Phase 3 readout for AR1001 decides whether Fosun Pharma adds $80 million to the $60 million option fee it paid in May. Among the Korean biotech events due that month, it is the one that ties a partner's cash directly to trial data.
Reality
- Evidence40
- Adoption
- Not scored
- Hype gap+20
- Incentives70
- Confidence45
Korea's home-built cyclotron cuts zirconium-89 imports to under 5% of supply
Korea Atomic Energy Research Institute's home-built RFT-30 cyclotron has cut Korea's reliance on imported zirconium-89 from 100% to under 5%. The institute also ships the isotope abroad, where its cyclotron research head says U.S. FDA approval could lift demand much further.
Reality
- Evidence40
- Adoption45
- Hype gap+15
- Incentives60
- Confidence45
Penn State lab modifies sterile-filtration membranes to remove microbes from injectable drugs
Penn State engineers are surface-modifying sterile-filtration membranes to remove microbes from injectable drugs, in work published in Biotechnology Journal. Doctoral candidate Shreya Kapila's own test for a new filter is that it removes organisms while leaving little of an expensive drug behind in the membrane.
Reality
- Evidence35
- Adoption
- Not scored
- Hype gap+10
- Incentives40
- Confidence40
E. coli persists longer in Georgia onion soils amended with poultry litter
E. coli survived longer in poultry-amended Georgia onion soils than in untreated soil across two seasons, a Risk Analysis study found. Humidity went with longer survival and wind with shorter, so growers' food-safety plans may need to reflect local weather.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+15
- Incentives
- Not scored
- Confidence50
Nature urges regulators to test AI medical devices in real clinics before deployment
Nature's editors want AI medical devices tested in real clinics, noting that just 19 of some 4,600 clinical AI papers were prospective randomized trials. Until the FDA decides, hospitals need to check whether a vendor's accuracy figure came from real patients or from a simulation.
Reality
- Evidence55
- Adoption50
- Hype gap+5
- Incentives
- Not scored
- Confidence55
Animal-free test methods still have to prove themselves against the animal experiments they would replace
Harvard's lung-on-a-chip has nearly 5,400 citations since 2010, but most non-animal test methods have yet to be rigorously tested, IEEE Spectrum reports. Validation means head-to-head runs against animal experiments, so animal data remains the yardstick for now.
Reality
- Evidence50
- Adoption20
- Hype gap+15
- Incentives45
- Confidence55
In rats, SWANS routes a front-paw signal through tissue to a hind-leg nerve implant
SWANS, described in Science, sent faint pulses about 40 centimeters through a rat's tissue to switch on a nerve-stimulating implant in its hind leg. Dropping the radio shrinks the devices to syringe size, though that range was measured only in rats.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+15
- Incentives
- Not scored
- Confidence50